NTLA rejected off the 17 level and retested high 15s as expected but looks like it's establishing a new support level around 16.25...If so, a couple hundred of my shares will be called away next Friday at 15.78 avg. so I'm waiting for next nice red opportunity to sell more 15 puts on this to keep reducing avg. cost. While I'm long CRSPR stocks (NTLA, EDIT & CRSP),...
NTLA has been flying through resistance levels from oversold conditions and looks like it's testing 17.28 resistance to establish it as support. If it closes above, likely going higher - if it rejects off of 17.28 then likely retest of high 15s before re-testing 17s. Apart from ongoing patent battles, this company was hit by a scientific paper that made unfounded...
Nice support level at $20 Filled Gap up and Gap down. If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels. CRISPR got upgraded. EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing...